59 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called
8-K
EX-99.1
ie2su7h3jq5
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
424B5
w252eg p719n3qn
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
vwrnyg2wof0
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
424B5
xrnv on586a7mtqn
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
xzby pns1lkhcfw74hn
23 Mar 22
Prospectus supplement for primary offering
5:14pm